Welgenaleucel - CISMeF

Preferred Label : Welgenaleucel;

NCIt definition : A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration, welgenaleucel targets, binds to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.;

Molecule name : UWC-19; UWC 19;

NCI Metathesaurus CUI : CL1413144;

Details

Origin ID

C175943;

UMLS CUI

C5446871;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients